about
The role of the subthalamic nucleus in L-DOPA induced dyskinesia in 6-hydroxydopamine lesioned ratsTwo opposite effects of Delta(9)-tetrahydrocannabinol on subthalamic nucleus neuron activity: involvement of GABAergic and glutamatergic neurotransmissionModulation of the subthalamic nucleus activity by serotonergic agents and fluoxetine administration.Pharmacological treatment of Parkinson's disease: life beyond dopamine D2/D3 receptors?Endocannabinoid modulation of dopaminergic motor circuits.Interaction between the 5-HT system and the basal ganglia: functional implication and therapeutic perspective in Parkinson's disease.Morphological Changes in a Severe Model of Parkinson's Disease and Its Suitability to Test the Therapeutic Effects of Microencapsulated Neurotrophic Factors.Topographical Distribution of Morphological Changes in a Partial Model of Parkinson's Disease--Effects of Nanoencapsulated Neurotrophic Factors Administration.Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson's disease.In vivo administration of VEGF- and GDNF-releasing biodegradable polymeric microspheres in a severe lesion model of Parkinson's disease.Nigrostriatal denervation changes the effect of cannabinoids on subthalamic neuronal activity in rats.Buspirone requires the intact nigrostriatal pathway to reduce the activity of the subthalamic nucleus via 5-HT1A receptors.Chronic L-DOPA administration increases the firing rate but does not reverse enhanced slow frequency oscillatory activity and synchronization in substantia nigra pars reticulata neurons from 6-hydroxydopamine-lesioned rats.Levodopa-induced dyskinesias in Parkinson disease are independent of the extent of striatal dopaminergic denervation: a pharmacological and SPECT study.Stimulatory effect of harmane and other beta-carbolines on locus coeruleus neurons in anaesthetized rats.Buspirone anti-dyskinetic effect is correlated with temporal normalization of dysregulated striatal DRD1 signalling in L-DOPA-treated rats.Preclinical pharmacology of F-98214-TA, a novel potent serotonin and norepinephrine uptake inhibitor with antidepressant and anxiolytic properties.Nanodelivery of Cerebrolysin and Rearing in Enriched Environment Induce Neuroprotective Effects in a Preclinical Rat Model of Parkinson's Disease.Deleterious Effects of VEGFR2 and RET Inhibition in a Preclinical Model of Parkinson's Disease.Imidazoline-induced inhibition of firing rate of 5-HT neurons in rat dorsal raphe by modulation of extracellular 5-HT levels.Excitatory regulation of noradrenergic neurons by L-arginine/nitric oxide pathway in the rat locus coeruleus in vivo.Inhibition of 5-hydroxytryptamine reuptake by the antidepressant citalopram in the locus coeruleus modulates the rat brain noradrenergic transmission in vivoThe stimulatory effect of clonidine on locus coeruleus neurons of rats with inactivated α2-adrenoceptors: involvement of imidazoline receptors located in the nucleus paragigantocellularisThe stimulatory effect of clonidine through imidazoline receptors on locus coeruleus noradrenergic neurones is mediated by excitatory amino acids and modulated by serotonin
P50
Q28482094-4E0C73B5-E3EA-488E-97D7-E6407911F891Q28580826-342ED5D2-78BF-42DA-95B8-EC9AC8F6B88DQ30575965-3DD31FB3-7C87-42A0-91F5-67D1AF4CFB02Q37077360-23317FB4-69CE-4E13-B3DC-702429BF79BFQ38018946-DD73C3C8-7FA8-40E7-9DCD-07044B82ECC3Q38199670-789AD009-6450-4224-B79C-9744E7AF18F5Q38731068-13538B69-3891-437A-95B7-513BD2F0CEF4Q38867773-DF1D5969-3E61-4BC9-9884-0468033413FFQ38985632-9C6A88F4-D91E-465B-8359-3BAD0088F114Q39156949-04207549-C916-47EC-B8CF-28FC14EA979BQ41809772-791AC19D-01E4-4D2B-9248-69340A4F59B3Q42486470-DF1E76E5-D189-4441-9F61-9274718A6DE1Q42488726-F5B3363C-E46B-4FA9-84FA-8D2F2F157907Q43255318-0FB30B6E-62CC-41FF-BA46-59343AEE9620Q43691749-7A996691-29F2-4D27-85DB-764EF2D07CC5Q43876923-7EB8EED7-C288-46EB-A362-1BAAE67517B9Q46609579-81AC70C3-FDC5-44E8-80CA-CD543838B109Q47755717-173450EF-2ACF-4F8B-9F54-BC62459B6671Q47907310-A3E5A2AB-C3D2-43A0-91DB-5D57BD46DE52Q48155081-351D17B5-5E5A-4F50-8797-0D7A2A9DCDBDQ48181631-E7830BAC-409C-4E5B-863C-40F21109BA18Q62082733-DB040EB7-25C4-44A3-A7B3-E3C7CAB4E5FFQ62082734-F24CC2B6-A6E3-4535-9ECF-E49BAF617AEFQ71523988-3344A926-B023-4F39-B6FF-FE42E0C3F2F8
P50
description
researcher ORCID ID = 0000-0003-2246-4378
@en
wetenschapper
@nl
name
Jose Angel Ruiz-Ortega
@ast
Jose Angel Ruiz-Ortega
@en
Jose Angel Ruiz-Ortega
@es
Jose Angel Ruiz-Ortega
@nl
type
label
Jose Angel Ruiz-Ortega
@ast
Jose Angel Ruiz-Ortega
@en
Jose Angel Ruiz-Ortega
@es
Jose Angel Ruiz-Ortega
@nl
prefLabel
Jose Angel Ruiz-Ortega
@ast
Jose Angel Ruiz-Ortega
@en
Jose Angel Ruiz-Ortega
@es
Jose Angel Ruiz-Ortega
@nl
P1153
6603458620
P21
P31
P496
0000-0003-2246-4378